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Objectives
 Provide an overview of the Transgender (TG) 
community 
 Summarize the cultural competencies and 
awareness of health disparities in the TG 
community 
 Discuss the health care needs of TG patients 
and how pharmacists can contribute to the 
treatment plan 
3
Epidemiology 
 Current National Statistics 
 1.4 million adults identify as transgender
 0.6% of adult population 
 2015 National Transgender Survey 
 27,715 participants
 Next survey in 2020  
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human 
Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Transgender People with HIV. Accessed December 22, 2019.
Redfern JS, Jann MW. The Evolving Role of Pharmacists in Transgender Health Care. Transgend Health. 2019;4(1):118–130. Published 2019 Apr 11. doi:10.1089/trgh.2018.0038
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Gender Identity
Identity Definition 
Gender identity One’s sense of being male or female, both or neither
Transgender Umbrella term for those whose gender identity and/or expression is different from sex assigned at birth 
Transgender man Born female and identifies as male
Transgender woman Born male and identifies as female 
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Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with 
HIV. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. 
Transgender People with HIV. Accessed December 22, 2019.
NOTE: Being TG does not suggest a particular sexual orientation
 Ask patients how they want to be addressed
Gender Affirmation 
 Process where person receives social, legal, 
psychological and medical support for their 
gender identity and expression
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of 
Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human 
Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. 
Transgender People with HIV. Accessed December 22, 2019.
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 Transgender ≠ medical term 
 DSM-5 Clinical Diagnosis: 
 Gender dysphoria
• A marked difference between gender identity and 
birth sex 
• Desire to be treated as the other gender and 
change sex characteristics
• Associated with clinically significant distress or 
impairment in social, occupational, or other 
important areas of functioning 
Clinical Diagnosis 
Redfern JS, Jann MW. The Evolving Role of Pharmacists in Transgender Health Care. Transgend Health. 2019;4(1):118–130. 
Published 2019 Apr 11. doi:10.1089/trgh.2018.0038
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 Coding Revision
 Transition from ICD 10 to ICD 11
• “Gender incongruence codes” from Mental Health
to a Sexual Health category   
Clinical Diagnosis 
Redfern JS, Jann MW. The Evolving Role of Pharmacists in Transgender Health Care. Transgend Health. 2019;4(1):118–130. 
Published 2019 Apr 11. doi:10.1089/trgh.2018.0038
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Overall Goal 
 To obtain lasting personal comfort and self 
acceptance in terms of body and gender role 
through affirmative psychotherapy and medical 
and/or surgical therapies
 Allow patients to live authentically 
Coleman E, Bockting W, Botzer M, et al. Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming 
People, Version 7. International Journal of Transgenderism. 2012;13(4):165-232. doi:10.1080/15532739.2011.700873
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Gender Transition
 Social 
 Dress or use of different names/pronouns 
 Being socially recognized as another gender 
 Medical interventions 
 Feminizing or masculinizing hormones
 Surgery 
• Ex: Breast removal (“top surgery”)
 Other interventions
 Facial hair removal, voice modification, genital 
tucking, packing, padding and chest binding 
Redfern JS, Jann MW. The Evolving Role of Pharmacists in Transgender Health Care. Transgend Health. 2019;4(1):118–130. Published 2019 Apr 11. 
doi:10.1089/trgh.2018.0038
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“TG persons not only have the same 
basic health needs in terms of 
screening, prevention, and treatment 
as their non-TG counterparts but also 
have clinical issues specifically related 
to or associated with gender 
incongruence” 
Redfern JS, Jann MW. The Evolving Role of Pharmacists in Transgender Health Care. Transgend Health. 2019;4(1):118–130. Published 
2019 Apr 11. doi:10.1089/trgh.2018.0038
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Health Disparities & the 
Role of Pharmacists 
12
Health Disparities 
Redfern JS, Jann MW. The Evolving Role of Pharmacists in Transgender Health Care. Transgender Health. 
2019;4(1):118-130. doi:10.1089/trgh.2018.0038
Discrimination 
Lack of Cultural Competence 
Financial Barriers 
Health System Barriers 
Socioeconomic Barriers 
Lack of Provider Expertise in TG Medicine 
13
Discrimination
 One-third (33%) of those sought medical 
attention experienced discrimination 
 Not using appropriate names and pronouns 
 Refusing to fill prescriptions or provide medical 
treatment  
 Consequences: 
 Social stress 
 Fear of being disrespected 
 Avoid or delay health visits 
James, S. E., Herman, J. L., Rankin, S., Keisling, M., Mottet, L., & Anafi, M. (2016). The Report of the 
2015 U.S. Transgender Survey. Washington, DC: National Center for Transgender Equality.
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Discrimination  
 Create a safe and culturally welcoming 
environment 
 Accountability and respect 
• Avoid insensitive comments and provide 
non-judgmental care   
 Communication
 Appropriate ways to learn about the patient
 The National LGBT Health Education Center  
• https://www.lgbthealtheducation.org/
15Redfern JS, Jann MW. The Evolving Role of Pharmacists in Transgender Health Care. Transgend Health. 
2019;4(1):118–130. Published 2019 Apr 11. doi:10.1089/trgh.2018.0038
Poor Cultural 
Competence
 Contributing factor to health care disparities 
Understand 
Terminology 
Challenge messages from 
cultures, families, religions, and 
peers influencing pharmacists’ 
beliefs or actions
Understand discrimination in 
our society 
Promote sensitive, responsive, 
and affirming TG healthcare
Cultural 
Competence
Redfern JS, Jann MW. The Evolving Role of Pharmacists in Transgender Health Care. Transgend Health. 2019;4(1):118–130. 
Published 2019 Apr 11. doi:10.1089/trgh.2018.0038
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Cultural Competence 
 Cultural humility
 Staff Training 
 National LGBT Education Center
 Environment
 Waiting areas/restrooms 
 Communication examples: 
17UCSF Transgender Care, Department of Family and Community Medicine, University of California San Francisco. Guidelines for the Primary and Gender-Affirming Care 
of Transgender and Gender Nonbinary People; 2nd edition. Deutsch MB, ed. June 2016. Available at transcare.ucsf.edu/guidelines.
Instead of: Say This:
How may I help you, Sir? How may I help you?
“She is here to pick up her 
prescription” 
The patient is here to pick up a 
prescription
Do you have a wife/husband? Do you have a partner or 
spouse?
Financial Barriers 
 Lack of income 
 In 2015, unemployment rate (15%) was 
three-times higher than U.S. population 
(5%) 
 Nearly one-third (29%) were living in 
poverty compared to the rate in U.S. 
population (14%)
 Sex work
• 1 in 5 (20%) have participated 
James, S. E., Herman, J. L., Rankin, S., Keisling, M., Mottet, L., & Anafi, M. (2016). The Report of the 2015 U.S. Transgender Survey. Washington, DC: 
National Center for Transgender Equality.
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Financial Barriers 
 Less likely to have insurance 
 In 2015, 14% were uninsured compared to 
11% of the U.S. population 
 Less access of preventative health services 
• Chronic conditions 
 Use of underground economy
• To access medications 
James, S. E., Herman, J. L., Rankin, S., Keisling, M., Mottet, L., & Anafi, M. (2016). The Report of the 2015 U.S. Transgender Survey. Washington, DC: 
National Center for Transgender Equality.
19
Financial Barriers
 Lack of Income/Insurance 
 Ensure that patients know where to access 
health care regardless of ability to pay 
 Patient Assistant Programs 
 Provide cost-effective options for medications 
dispensed 
 Assist in the process of insurance denials and 
prior authorizations
 Educate patient on dangers of purchasing 
products of underground economy 
Redfern JS, Jann MW. The Evolving Role of Pharmacists in Transgender Health Care. Transgend Health. 2019;4(1):118–130. Published 
2019 Apr 11. doi:10.1089/trgh.2018.0038
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Health System 
Barriers
 Legal documents
 Federal
• Passport and Social Security Card
 State: 
• Florida: Name, Driver’s License, and Birth 
Certificate
 Disparities in electronic medical records
 Gender identity vs. Birth sex 
 Laboratory references 
 Advocate for two-step process
Redfern JS, Jann MW. The Evolving Role of Pharmacists in Transgender Health Care. Transgend Health. 2019;4(1):118–130. Published 
2019 Apr 11. doi:10.1089/trgh.2018.0038
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Health System 
Barriers
 Examples of legal records not matching 
physical patient 
 Outpatient
• Prescription Drug Monitoring Program  
 Inpatient 
• Medication Clarification Process
• Discharge counseling 
Redfern JS, Jann MW. The Evolving Role of Pharmacists in Transgender Health Care. Transgend Health. 2019;4(1):118–130. Published 
2019 Apr 11. doi:10.1089/trgh.2018.0038
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Health System 
Barriers 
 Laboratory References  
 Normal values not established for patients 
receiving hormonal or surgical interventions
 Depends on patient’s current hormone therapy 
 No hormonal/surgical intervention = birth sex 
values 
 No surgery + stable hormone therapy = affirmed 
gender 
UCSF Transgender Care, Department of Family and Community Medicine, University of California San Francisco. Guidelines for the Primary and Gender-Affirming Care of 
Transgender and Gender Nonbinary People; 2nd edition. Deutsch MB, ed. June 2016. Available at transcare.ucsf.edu/guidelines.
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Health System 
Barriers 
 Examples:
 Patient CJ (TG woman)
• Potential ↓ muscle mass, potential ↓ SCr 
 Patient CB (TG man)
• ↑ Testosterone, ↑ Hematocrit 
UCSF Transgender Care, Department of Family and Community Medicine, University of California San Francisco. Guidelines for the Primary and Gender-Affirming Care of 
Transgender and Gender Nonbinary People; 2nd edition. Deutsch MB, ed. June 2016. Available at transcare.ucsf.edu/guidelines.
Lab Measures 
Transgender Women on 
Hormone Therapy 
Transgender Men on 
Hormone Therapy 
Lower Limit Upper Limit Lower Limit Upper Limit 
Alkaline Phosphatase N/D Male value N/D Male value 
Serum Creatinine N/D Male value N/D Male value
Hemoglobin / Hematocrit Female value Male value Male value* Male value 
N/D = Not defined *Male value if amenorrheic 
24
Health System 
Barriers
 Renal function 
 Preferred Cystatin C-based GFR calculations for 
marginal renal function
• Independent of muscle mass
• More accurate
 How do we calculate with Cockcroft-Gault 
Equation?
25UCSF Transgender Care, Department of Family and Community Medicine, University of California San Francisco. Guidelines for the Primary and Gender-Affirming 
Care of Transgender and Gender Nonbinary People; 2nd edition. Deutsch MB, ed. June 2016. Available at transcare.ucsf.edu/guidelines
Socioeconomic 
Barriers
 Homeless 
 30% lifetime homelessness 
 Mental health 
 40% attempted suicide in their lifetime (9 times 
the attempted rate in the U.S. population 4.6%) 
 Alcohol/substance abuse 
 29% illicit drug use vs. 10% of U.S population  
 Smoking
 22% are current smokers vs. 21% of U.S. 
population
 Health-Related Risks 
James, S. E., Herman, J. L., Rankin, S., Keisling, M., Mottet, L., & Anafi, M. (2016). The Report of the 2015 U.S. 
Transgender Survey. Washington, DC: National Center for Transgender Equality
26
Socioeconomic 
Barriers
 Increase cultural competence and provide a 
welcoming environment   
 Medication counseling 
 Ex: Hormone therapy, antidepressants, smoking 
cessation options, etc.  
• Discuss risks when using hormone therapy 
27UCSF Transgender Care, Department of Family and Community Medicine, University of California San Francisco. Guidelines for the Primary and Gender-
Affirming Care of Transgender and Gender Nonbinary People; 2nd edition. Deutsch MB, ed. June 2016. Available at transcare.ucsf.edu/guidelines.
Socioeconomic 
Barriers
 Counsel on Health Prevention 
 Diet/Exercise 
 Pre-Exposure Prophylaxis (PrEP) or Treatment 
• 1.4% of TG were living with HIV compared to U.S. general 
population 0.3%
 Hepatitis
• Hazards of sharing needles
 Screenings 
• Treat the anatomy that is present: If you have it, 
check it!
• Pap-smears, colonoscopy, prostate checks, 
mammograms, etc. 
28Redfern JS, Jann MW. The Evolving Role of Pharmacists in Transgender Health Care. Transgend Health. 2019;4(1):118–130. Published 
2019 Apr 11. doi:10.1089/trgh.2018.0038
James, S. E., Herman, J. L., Rankin, S., Keisling, M., Mottet, L., & Anafi, M. (2016). The Report of the 2015 U.S. Transgender Survey. Washington, DC: National Center for 
Transgender Equality.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available 
at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Transgender People with HIV. Accessed December 22, 2019.
Lack of Providers with 
Expertise
 Negative Experiences 
 24% had to teach their provider about being 
transgender for appropriate care 
 Verbally harassed 
 Refusal to provide care 
29
James, S. E., Herman, J. L., Rankin, S., Keisling, M., Mottet, L., & Anafi, M. (2016). The Report of the 2015 U.S. Transgender Survey. Washington, DC: National Center for 
Transgender Equality.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available 
at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Transgender People with HIV. Accessed December 22, 2019.
Education
 Off-label use of medications 
 Risks and benefits
 Drug-Disease Interactions
 Drug-Drug Interactions 
30
Off-label Use of
Medications 
 Benefits of cross-sex hormone therapy
31
Feminizing Effects Masculinizing Effects 
 Decreased testicular size/sperm production  Deepened voice 
 Erectile dysfunction  Clitoral enlargement (variable) 
 Breast growth (variable)  Growth in facial and body hair
 Body fat redistribution  Cessation of menses and vaginal atrophy 
 Decreased muscle mass  Atrophy of breast tissue 
 Thinning and slowed growth of body and 
facial hair 
 Decreased percentage of body fat 
compared to muscle mass 
Coleman E, Bockting W, Botzer M, et al. Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 
7. International Journal of Transgenderism. 2012;13(4):165-232. doi:10.1080/15532739.2011.700873.
Hormone Therapy
Hormone Side Effects 
Estrogens 
• Estradiol $
• Conjugated equine estrogens 
• Migraines
• Weight gain 
• Mood swings, insomnia
• Hot flashes
Antiandrogens
• Spironolactone $ • Hyperkalemia• Polydipsia
• Polyuria
• Orthostatic hypotension 
• 5-Alpha-Reductase Inhibitors
• Finasteride/Dutasteride • Impotence • Ejaculatory disorders 
Gonadotropin-Releasing Hormone Agonists (GnRHs)
• Goserelin/Leuprolide/Nadarelin $$$ • Insomnia • Headaches 
Progestogens
• Medroxyprogesterone • Headaches
• Depression 
• Weight gain 
• Insomnia 
Testosterones
• Testosterone • Hypertension • Acne 
UCSF Transgender Care, Department of Family and Community Medicine, University of California San Francisco. Guidelines for the Primary and Gender-Affirming Care of Transgender and 
Gender Nonbinary People; 2nd edition. Deutsch MB, ed. June 2016. Available at transcare.ucsf.edu/guidelines.
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Formulations & 
Dosing
Hembree,W. C, Cohen-Kettenis, P., Gooren, L. et al, Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical 
Endocrinology & Metabolism, Volume 102, Issue 11, 1 November 2017, Pages 3869–3903, https://doi.org/10.1210/jc.2017-01658
Class Medication/Formulation  Dose range 
Estrogen 
• Estradiol – oral • 2-6 mg/day
• Estradiol – transdermal patch • 0.025-0.2 mg/day 
• Estradiol – Parenteral 
(valerate or cypionate) 
• 5-30 mg IM every 2 weeks OR
• 2-10 mg IM every week 
Antiandrogens
• Spironolactone • 100 – 300 mg/day 
• GnRHs • 3.75 mg SQ monthly 
• 11.25 mg SQ every 3 months 
Testosterone 
• Testosterone cypionate • 100-200 mg SQ (IM) every 2 
weeks OR
• 50 – 100 mg every week 
• Testosterone gel • 50-100 mg/day 
• Testosterone patch • 2.5-7.5 mg/day 
IM – intramuscular 
SQ – subcutaneous 
33
Monitoring Parameters
Hembree,W. C, Cohen-Kettenis, P., Gooren, L. et al, Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical 
Endocrinology & Metabolism, Volume 102, Issue 11, 1 November 2017, Pages 3869–3903, https://doi.org/10.1210/jc.2017-01658
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Test Recommendations
• BUN/SCr/K • At baseline and every 3 months or as needed with Spironolactone 
• Estradiol • Every 3 months* and as needed
• Maintain estradiol serum levels (100-200 pg/mL)
• Maintain testosterone levels < 50ng/dL 
• Testosterone • Every 3 months* and as needed
• Maintain testosterone levels (320-1000 ng/dL)
• Albumin** • Every 3 months* and as needed
• Prolactin • Only if symptoms of prolactinoma or as needed
• Sex Hormone Binding 
Globulin (SHBG) 
• Every 3 months* and as needed
*in the first year of therapy only
**used to calculate bioavailable testosterone 
Clinical Pearls
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Hormone Clinical Pearls
• Estradiol • Bioidentical hormone to human ovary 
• VTE risk: patch formulation is preferred (first pass effect)
• Cost effective option 
• Contraindicated in active estrogen sensitive cancers 
• Conjugated equine estrogens • Not accurately measured in estradiol assays 
• Spironolactone • Cost effective option 
• Used for gynecomastia effects 
• Used in combination with lower estrogen dosing to avoid 
associated risks of high estrogen levels 
• Provides an option for hypertensive patients 
• 5-alpha reductase inhibitors 
(Finasteride, Dutasteride)
• Option for: 
• For those unable to tolerate, or with contraindications to 
use of Spironolactone 
• Those seeking partial feminization
• Those who continue to exhibit virilized features or hair 
loss after complete androgen blockade or orchiectomy  
• Gonadotropin-Releasing
Hormone Agonists
• Once a month or 3-month administration 
• Testosterone • Gel: easy application, less irritation than patches 
• Injection: less frequent dosing than topical applications 
UCSF Transgender Care, Department of Family and Community Medicine, University of California San Francisco. Guidelines for the Primary and Gender-Affirming 
Care of Transgender and Gender Nonbinary People; 2nd edition. Deutsch MB, ed. June 2016. Available at transcare.ucsf.edu/guidelines
Hormone Therapy 
Risks
Risk level Estrogen Testosterone 
• Very high risk • Thromboembolic disease • Erythrocytosis (hematocrit >50%) 
• Moderate risk
• Macroprolactinoma 
• Breast cancer 
• Coronary artery disease 
• Cerebrovascular disease 
• Cholelithiasis
• Hypertriglyceridemia 
• Severe liver dysfunction
(transaminases > threefold upper 
limit of normal 
• Coronary artery disease 
• Cerebrovascular disease 
• Hypertension 
• Breast or uterine cancer 
Hembree,W. C, Cohen-Kettenis, P., Gooren, L. et al, Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical 
Endocrinology & Metabolism, Volume 102, Issue 11, 1 November 2017, Pages 3869–3903, https://doi.org/10.1210/jc.2017-01658
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VTE Risk
37
Transdermal 
Estrogen
VTE due to 
medication 
use
Family 
History of 
VTE 
History of 
VTE
UCSF Transgender Care, Department of Family and Community Medicine, University of California San Francisco. Guidelines for the Primary and Gender-Affirming 
Care of Transgender and Gender Nonbinary People; 2nd edition. Deutsch MB, ed. June 2016. Available at transcare.ucsf.edu/guidelines
Cardiovascular Risk 
Assessment  
 AHA/ACC Guidelines
 Sex-specific calculators for risk and interventions
• ASCVD Calculator 
• http://tools.acc.org/ASCVD-Risk-Estimator-
Plus/#!/calculate/estimate/
 No current guidance for TG population
 The Center of Excellence for Transgender Health
 Use risk calculator for sex at birth, affirmed 
gender or an average of the two depending on: 
• Age at which patient began using hormone and 
• Total duration of hormone therapy  
38UCSF Transgender Care, Department of Family and Community Medicine, University of California San Francisco. Guidelines for the Primary and Gender-Affirming 
Care of Transgender and Gender Nonbinary People; 2nd edition. Deutsch MB, ed. June 2016. Available at transcare.ucsf.edu/guidelines
ASCVD: Atherosclerotic cardiovascular disease 
Diabetes Screening 
 American Diabetes Association Practice 
Guidelines 
 Recommendations for screening in transgender 
patient do not differ from current guidelines
 World Professional Association of 
Transgender Health – Standards of Care 
 Recommend that diabetes be “reasonably 
controlled” prior to initiating therapy  
39UCSF Transgender Care, Department of Family and Community Medicine, University of California San Francisco. Guidelines for the Primary and Gender-Affirming 
Care of Transgender and Gender Nonbinary People; 2nd edition. Deutsch MB, ed. June 2016. Available at transcare.ucsf.edu/guidelines
Bone Health 
 Risk for osteoporosis increases after 
gonadectomy for both transgender men and 
women
 Screening 
• Begin bone density at age 65
• For risk factors, start between 50-64
• Currently based on age and sex 
40Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human 
Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Transgender People with HIV. Accessed December 22, 2019.
HIV Management
 PrEP 
 No known drug-drug interactions with gender-
affirming hormones   
 Concurrent treatment with hormone therapy is 
NOT contraindicated 
 Treatment 
 Drug interactions 
 Emphasize medication counseling 
41Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human 
Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Transgender People with HIV. Accessed December 22, 2019.
Drug-Drug Interactions
42
Antiretroviral Hormone therapy Effect Recommendation 
• Elvitegravir/cobicistat 
• All boosted Protease
Inhibitors
• Dutasteride
• Finasteride 
• Testosterone 
ARV 
Concentrations
of GAHT 
 dose of GAHT drugs as 
needed to achieve the desired 
clinical effects and hormone 
concentrations 
• Protease
Inhibitors/ritonavir
• Efavirenz 
• Etravirine 
• Nevirapine 
• Estradiol
ARV 
concentrations 
of GAHT 
 Dose of GAHT to achieve the 
desired clinical effects and 
hormone concentrations 
• Efavirenz 
• Etravirine 
• Nevirapine 
• Dutasteride 
• Finasteride 
• Testosterone
• Elvitegravir/cobicistat
• Protease 
inhibitor/cobicistat • Estradiol 
Unclear effect 
on GAHT 
Potential for  or  estradiol 
concentrations. Adjust estradiol 
dose to achieve desired clinical 
effects  
ARV: antiretroviral 
GAHT: gender-affirming hormone therapy 
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. 
Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Transgender People with HIV. Accessed December 22, 2019.
Take Away Points
 Focus on gender neutral language
 Create a safe and supportive environment for a 
marginalized and underserved population 
 Provide counseling – we are the medication 
experts
 Utilize the available resources to become more 
educated and culturally competent 
Healthcare 
Disparities Education 
Improved 
Outcomes
43
Assessment 
 The term transgender encompasses 
a wide spectrum of individuals whose 
gender identity, gender expression, 
or behavior conform to that typically 
associated with the sex assigned to 
them at birth?
 True 
 False 
44
Assessment 
 Pharmacists can play a key role in 
assisting TG patients with medication 
access programs
 True 
 False 
45
Assessment 
One of the disparities in health care 
for TG patients is lack of expertise in 
TG medicine 
 True 
 False 
46
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